SCHEMBL2635846

SCHEMBL2635846

O=C(O)N1CCN(C(=O)O)[C@@H](c2ccc(Br)cc2)C1

nearest known ligand 0.43

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
EIF4A3 P38919 13/20 0.43
P2RX7 Q99572 1/20 0.41
HRH3 Q9Y5N1 2/20 0.37
KDM4E B2RXH2 1/20 0.37
GMNN O75496 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
BLM P54132 1/20 0.37
KMT2A Q03164 1/20 0.37
NR1H2 P55055 1/20 0.37
NR1H3 Q13133 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2635873 1.00 EIF4A3 (0.43) EIF4A3P2RX7HRH3KDM4EGMNN
SCHEMBL2507077 0.84 P2RX7 (0.41) EIF4A3P2RX7
SCHEMBL82172 0.83 NR1H2 (0.57) EIF4A3KMT2ANR1H2NR1H3
SCHEMBL12988184 0.83 NR1H2 (0.57) EIF4A3KMT2ANR1H2NR1H3
SCHEMBL5533317 0.81 EIF4A3 (0.46) EIF4A3P2RX7HRH3ALDH1A1
SCHEMBL83462 0.81 EIF4A3 (0.46) EIF4A3P2RX7HRH3ALDH1A1
SCHEMBL16530352 0.80 ALDH1A1 (0.42) ALDH1A1KMT2A
SCHEMBL27201661 0.76 ALDH1A1 (0.41) P2RX7KDM4EALDH1A1LMNANR1H2
SCHEMBL25322608 0.74 MAPT (0.58) ALDH1A1LMNA
SCHEMBL18343896 0.74 RIPK1 (0.38) HRH3ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129377-B2 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-03-06 US disclosed
EP-2266969-A2 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors Mitsubishi Tanabe Pharma Corporation (JP) 2010-12-29 EP disclosed
EP-2261224-A2 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors Mitsubishi Tanabe Pharma Corporation (JP) 2010-12-15 EP disclosed
US-20090239864-A1 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS MITSUBISHI PHARMA CORPORATION (JP) 2009-09-24 US disclosed
EP-1805164-A2 6-(PYRIDINYL)-4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS Mitsubishi Pharma Corporation (JP) 2007-07-11 EP disclosed
WO-2006036015-A2 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS MITSUBISHI PHARMA CORPORATION (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239864-A1 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS MAPT, TTBK1, PSEN1 EIF4A3 1744/4885P2RX7 3153/4885HRH3 933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.